Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
It is not a GLP-1 receptor agonist
Diabetes Obes Metab 19(3):33647 Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
NICE guidelines (NG28) recommend specific injectable GLP-1 receptor agonists for type 2 diabetes management in appropriate clinical contexts
.png)
She is a dentist and accomplished medical and scientific writer known for her commitment to bridging the gap between clinical expertise and accessible healthcare information
Experimental investigations have demonstrated that cholangiocytes are sensitive to GLP-1 and respond with augmented proliferation, potentially increasing the risk of duct obstruction [47,48]
US$ 25.18
US$ 22.34
US$ 22.81
US$ 26.57
